Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
siRNA
Biotech
ADARx scores upsized $446M IPO, while City maps out Nasdaq plans
ADARx Pharmaceuticals has overshot its own IPO ambitions, as fellow RNA-focused biotech City Therapeutics also plans a public listing.
James Waldron
Sep 25, 2026 2:46am
AbbVie-backed ADARx plans IPO to fund array of siRNA med trials
Sep 6, 2026 2:25pm
Silence brings the noise to Takeda with phase 2 blood cancer win
Aug 10, 2026 7:31am
AstraZeneca pays CSPC $30M to form kidney drug discovery pact
Jul 3, 2026 8:00am
Novartis dystrophy data tee up regulatory talks on Avidity drug
Jun 12, 2026 4:30am
Alnylam pays Inceptive $30M to transform siRNA design
Jun 4, 2026 4:13am
